Clinical Trials Logo

Carcinogenesis clinical trials

View clinical trials related to Carcinogenesis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06007300 Not yet recruiting - Clinical trials for the Dynamic Evolution of Endometrial Carcinogenesis

A Multiomics Study Based on the Dynamic Evolution of Endometrial Carcinogenesis

Start date: August 2023
Phase:
Study type: Observational

The goal of this observational study is to draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of the dynamic evolution of endometrial carcinogenesis in 100 patients with normal endometrium, 100 patients with atypical endometrial hyperplasia, and 100 patients with endometrial cancer; and then to explore the underlying molecular mechanism, and establish the database system for the dynamic evolution of endometrial carcinogenesis.

NCT ID: NCT03261752 Not yet recruiting - Colo-rectal Cancer Clinical Trials

New Genes in the Carcinogenesis of Colorectal Cancer

Start date: October 1, 2018
Phase:
Study type: Observational

Colo rectal cancer is one of the greatest ,mutual malignancies worldwide ,accounting for an estimated 1.3 million new cases and >500,000 mortality ⁄ year . is the fourth leading cause of cancer-associated mortality worldwide with speedily ,cumulative ,occurrence rate in the worldwide

NCT ID: NCT03188315 Not yet recruiting - Clinical trials for DNA Virus Infections

Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Cancer is a devastating disease, presenting an immense disease burden to affected individuals and their families as well as health care systems with 10.9 million new cases and 6.7 million deaths per year. Approximately 12% of human cancers worldwide are caused by oncoviruses infection with more than 80% of cases occurring in the developing world. Tumor viruses can be classified into two groups based on their genetic material; 1. DNA tumor viruses: 1. Small DNA tumor viruses (Papilloma viruses, Polyoma viruses and adenoviruses). 2. Complex DNA tumor viruses (Herpes viruses and Hepatitis B viruses). 2. RNA tumor viruses ( Hepatitis C viruses and human T-cell leukemia virus "HTLV"). There are around 100 types of HPV, with different variations in their genetic and oncogenic potential [5]. Thus, HPV genotypes are divided into 2 groups based on their vulnerability; High risk HPV (HR-HPV) and low risk HPV (LR-HPV). The HPV genome encodes several oncoproteins [5]. E6 and E7 are the main genes responsible for cell transformation mediated by HR-HPV, and they modulate the activities of cellular proteins that regulate the cell cycle. Thus, the presence of E6/E7 can be a specific marker for diagnosing precancerous lesions by HPV. Knowledge of the etiology of virus-mediated carcinogenesis, the networking of pathways involved in the transition from infection to cancer and the risk factors associated with each type of cancer, all suggest prophylactic and therapeutic strategies that may reduce the risk of virus-mediated cancer.

NCT ID: NCT02638402 Not yet recruiting - Ovarian Cancer Clinical Trials

Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers

Start date: May 2016
Phase: N/A
Study type: Observational

To clarify the critical role of glycosyltransferases, altered Mucins, and RTKs in human ovarian and endometrial neoplasms, the study will examine the immunohistochemical expression profiles of glycosyltransferases, Mucins and receptor tyrosin kinases (RTKs) family in various stages and/or histologic subtypes of human ovarian and endometrial neoplasms and tissue microarrays.